Liver cancer 2024 Aug 12
Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma.
Related Questions
As opposed to Atezolizumab/Bevacizumab or Durvalumab/Tremelimumab.
New answer by Medical Oncologist at Mayo Clinic, Rochester (May 2, 2025)
Great question! CheckMate 9DW with the combination IPI3/NIVO1 compared to sorafenib/lenvatinib (85% were lenvatinib in the control arm) significantly improved OS (23.7 months ...